Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

60P - ALKBH1 alterations predict poor prognosis in oral squamous cell carcinoma

Date

15 Oct 2022

Session

Poster display session

Presenters

Paramasivam Arumugam

Citation

Annals of Oncology (2022) 33 (suppl_8): S1383-S1430. 10.1016/annonc/annonc1095

Authors

P. Arumugam1, V.P. Jayaseelan2, M. Senthil Murugan3

Author affiliations

  • 1 Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai/IN
  • 2 Centre for Cellular and Molecular Research, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai/IN
  • 3 Department of Oral Surgery, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University,, Poonamallee/IN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 60P

Background

Oral squamous cell carcinoma (OSCC) remains the leading cause of cancer-related deaths worldwide. Despite extensive research on OSCC, the pathogenesis of OSCC is not fully understood. ALKBH1 is a mammalian RNA demethylase responsible for the demethylation of N6-methyladenosine (m6A) in RNA and numerous recent studies reported that ALKBH1 plays an important role in tumorigenesis and metastasis, but the role of ALKBH1 in OSCC is largely unknown.

Methods

In this study, we investigated the genetic alterations of the ALKBH1 gene in HNSCC and their association with clinicopathological features, including survival using openly available data from The Cancer Genome Atlas (TCGA). In addition, we have sequenced the complete ALKBH1 gene in 126 OSCC patients.

Results

We found that the genetic alterations of the ALKBH1 gene were significantly associated with clinicopathological features as well as TP53 mutation. Patients with mutation of the ALKBH1 gene had worse overall survival (OS). Truncating mutation of ALKBH1 gene predicted poor OS of OSCC patients. In addition, we identified several ALKBH1 missense mutations, including novel mutations in OSCC patients, and in silico analyses indicated that these mutations could be potentially pathogenic. Moreover, mutations in the ALKBH1 gene were also associated with nodal metastasis.

Conclusions

Our results suggest that ALKBH1 alterations were significantly associated with poor prognosis and may represent a new marker of prognosis in OSCC.

Legal entity responsible for the study

The authors.

Funding

Indian Council of Medical Research (Grant No. DHR-GIA, 2020-9530).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.